Evidence map›Paper›PMID 38970065›Full record

ArticleTrials2024

An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.

Rindra Vatosoa Randremanana, Mihaja Raberahona, Mamy Jean de Dieu Randria, Josephine Bourner, Gabriella Zadonirina, Hanitra Razananaivo, Théodora Mayouya-Gamana, Reziky Mangahasimbola, Elise Pesonel, Annelies Gillesen and 5 more

Registry-linked trialAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04110340 (An Open-label, Randomised, Non-inferiority Trial of the Efficacy and Safety of Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin in the Treatment of Bubonic Plague), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04110340 phase3completednot on this map

An Open-label, Randomised, Non-inferiority Trial of the Efficacy and Safety of Ciprofloxacin Versus an Aminoglycoside Followed by Ciprofloxacin in the Treatment of Bubonic Plague

TypeinterventionalSponsorUniversity of OxfordRan2020 to 2025Enrolled222ConditionsPlague, Bubonic, Plague, PneumonicArmsCiprofloxacin, Streptomycin, Gentamicin
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Rindra Vatosoa RandremananaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Mihaja RaberahonaCentre d'Infectiologie Charles Mérieux, University of Antananarivo, Antananarivo, Madagascar.
Mamy Jean de Dieu RandriaDepartment of Infectious Diseases, University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar.
Josephine BournerISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK. josephine.bourner@ndm.ox.ac.uk.ORCID http://orcid.org/0000-0003-4687-8380
Gabriella ZadonirinaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Hanitra RazananaivoInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Théodora Mayouya-GamanaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Reziky MangahasimbolaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Elise PesonelISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Annelies GillesenISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Minoarisoa RajerisonInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Voahangy AndrianaivoarimananaInstitut Pasteur de Madagascar, Antananarivo, Madagascar.
Tansy EdwardsLondon School of Hygiene and Tropical Medicine, London, UK.
Peter HorbyISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Piero OlliaroISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK.

Funding

UK Foreign Commonwealth and Development Office and Wellcome 216273/Z/19/ZWellcome Trust
6 · The paper itself

Abstract

This article reports an update to the protocol of the IMASOY trial, which was prospectively registered on clinicaltrials.gov (NCT04110340) in October 2019.

Indexed as

Anti-Bacterial AgentsCiprofloxacinAminoglycosidesAnimalsDrug Therapy, CombinationEquivalence Trials as TopicHumansPlagueRandomized Controlled Trials as TopicTreatment OutcomeAminoglycosidesAnti-Bacterial AgentsCiprofloxacin

Identifiers

PMID38970065
PMCPMC11227148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.